0 items in cart
Allergy Therapeutics [AGYTF]
Reports for Purchase
Showing records 1 - 20 ( 31 total )
Company: Allergy Therapeutics
Price: 12.50
Company: Allergy Therapeutics
VLP Peanut Clears First Hurdle; Grass Program on Track For Interim Phase 3 Data in 4Q; Rating Under Review, PT Suspended
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Price: 12.50
Company: Allergy Therapeutics
Start of pivotal Grass MATA MPL Phase III trial
Provider: Trinity Delta
Analyst: GREGOREK L
Price: 5.00
Company: Allergy Therapeutics
Start of pivotal Grass MATA MPL Phase III trial
Provider: Trinity Delta
Analyst: GREGOREK L
Price: 5.00
Company: Allergy Therapeutics
Moderating FY2023 Revenue Expectations on Manufacturing Pause; Clinical Programs Remain on Track; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Price: 12.50
Company: Allergy Therapeutics
Manufacturing pause takes it toll on revenues
Provider: Trinity Delta
Analyst: GREGOREK L
Price: 5.00
Company: Allergy Therapeutics
FY2022 Results; Expects Return to Revenue Growth in FY2023; Lead Pipeline Programs on Track For Top-Line Data in 2023
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Price: 12.50
Company: Allergy Therapeutics
On the starting blocks towards key data expected in 2023
Provider: Trinity Delta
Analyst: GREGOREK L
Price: 12.50
Company: Allergy Therapeutics
Got Milk? Antidotes to Allergies Including Peanut and Pollen on the Way; Initiating With a Buy and 100p Price Target
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Price: 75.00
Company: Allergy Therapeutics
Key data on track, return to growth expected next year
Provider: Trinity Delta
Analyst: GREGOREK L
Price: 5.00
Company: Allergy Therapeutics
Solid commercial performance with major R&D upside
Provider: Trinity Delta
Analyst: GREGOREK L
Price: 35.00
Company: Allergy Therapeutics
Solid commercial performance with major R&D upside
Provider: Trinity Delta
Analyst: GREGOREK L
Price: 35.00
Company: Allergy Therapeutics
FDA green lights VLP Peanut vaccine Phase I trial
Provider: Trinity Delta
Analyst: GREGOREK L
Price: 5.00
Company: Allergy Therapeutics
FDA green lights VLP Peanut vaccine Phase I trial
Provider: Trinity Delta
Analyst: GREGOREK L
Price: 5.00
Company: Allergy Therapeutics
Commercialising and developing a differentiated portfolio
Provider: Trinity Delta
Analyst: GREGOREK L
Price: 5.00
Company: Allergy Therapeutics
Positive top line G309 results for Grass MATA MPL
Provider: Trinity Delta
Analyst: GREGOREK L
Price: 5.00
Company: Allergy Therapeutics
FY21 results show continued strong growth
Provider: Trinity Delta
Analyst: GREGOREK L
Price: 25.00
Company: Allergy Therapeutics
VLP Peanut heading towards US Phase I studies
Provider: Trinity Delta
Analyst: GREGOREK L
Price: 25.00
Company: Allergy Therapeutics
VLP Peanut heading towards US Phase I studies
Provider: Trinity Delta
Analyst: GREGOREK L
Price: 25.00
Company: Allergy Therapeutics
Biomarker data confirm VLP Peanut hypoallergenicity
Provider: Trinity Delta
Analyst: GREGOREK L
Price: 10.00